Both oxygenation and rhythmic stretching of the lungs are factors known to be responsible for pulmonary vasodilation at birth. Based on our previous studies, we proposed that the pulmonary vasodilation caused by oxygen could be mediated, at least in part, through bradykinin release. To test this hypothesis, we evaluated the cardiovascular responses to in utero ventilation during infusion of a B,-subtype bradykinin receptor antagonist (BKA), [N-adamantaneacetyl-~-Arg~,Hyp',Thi~~~,~-Phe~]bradykinin, at 15-20 pg.kg-'.min-l in eight near-term fetal lambs and during drug vehicle infusion in five control fetal lambs. Prostacyclin synthesis was inhibited by meclofenamate infusion (1.5 rngkg-'.hK1). Surgical placement of vascular catheters, a flow transducer around the left pulmonary artery, and a tracheostomy tube and formalin infiltration of the ductus arteriosus to maintain its patency in the presence of meclofenamate were performed 72 h before the study. Hemodynamic variables and pulmonary blood flow were measured and pulmonary vascular resistance was Shortly after birth, after the onset of pulmonary ventilation, pulmonary vascular resistance and pulmonary arterial pressures fall rapidly. As a consequence, pulmonary blood flow increases approximately 8-to 10-fold (1).
calculated before and after in utero ventilation with 100% oxygen. Despite complete blockade by BKA of the pulmonary vasodilation produced by exogenous bradykinin, ventilation with oxygen significantly increased pulmonary blood flow by 676% over baseline state (157.8 2 66 to 1224 t 265 mL.min-'el00 g-', p < 0.01) and decreased the pulmonary vascular resistance by 89% from baseline state (0.44 t 0.16 to 0.048 t 0.01 t0rr.rnL-'.min-l00g,~ < 0.01). Such responses to ventilation with oxygen were comparable to those noted in the control animals, in whom bradykinin receptors had not been blocked. We conclude that bradykinin receptor blockade does not inhibit or attenuate the pulmonary vasodilatory response caused by oxygen in fetal lambs, thereby suggesting that bradykinin release is not critical for oxygen-mediated pulmonary vasodilation.
(Pediafr Res 36: 474480, 1994)
Abbreviations EDNO, endothelium-derived nitric oxide distention of the lungs produces pulmonary vasodilation mainly via the cyclooxygenase pathway and prostaglandin production (2) (3) (4) (5) .
The exact mechanisms of oxygenation-induced pulmonary vasodilation remain incompletely understood. Oxygen may act directly on the smooth muscle in the vessel wall or via the release of endogenous vasoactive substances. Bradykinin was considered to be one such vasoactive substance, and the pulmonary vasodilator action of exogenous bradykinin in the fetus has been welldemonstrated (6-10). Oxygenation of the fetal lamb, by exposure to hyperbaric oxygen without ventilation, stimulates bradykinin production and also causes pulmonary vasodilation (11). Bradykinin induces the secondary release of additional vasoactive substances, including prostaglandins (10, 12) and EDNO (13), which could, in turn, mediate the pulmonary vasodilation produced by bradykinin. It is not known to what extent local bradykinin release is involved in the pulmonary vasodilation caused by oxygen or whether oxygen additionally has a direct vasodilator effect or directly induces local production of another vasoactive substance, perhaps EDNO (14) .
Based on these observations and our earlier studies, which showed that oxygenation of the fetus stimulated the production of bradykinin (ll), we hypothesized that the pulmonary vasodilation caused by ventilation with oxygen may be mediated through the release of bradykinin. To test this hypothesis, in near-term fetal lambs, we evaluated the effects on pulmonary blood flow and pulmonary vascular resistance of in utero ventilation with oxygen in the presence or absence of a potent bradykinin receptor antagonist. With use of strict aseptic precautions, a midline laparotomy was performed to expose the uterus; through a small uterine incision, the fetal hind limb was exposed. Lidocaine hydrochloride (1%) was infiltrated LC., and 20 mg of ketamine hydrochloride were given intramuscularly to provide analgesia for the fetus. Catheters were inserted into the inferior vena cava and descending aorta of the fetus via hind-limb vessels. A catheter was also introduced into the amniotic cavity to measure amniotic fluid pressure.
METHODS

Surgical
Through a separate uterine incision, the left chest of the fetus was exposed; a fetal thoracotomy was performed in the third left intercostal space to expose the heart and great vessels. Succinylcholine hydrochloride (Organon, Inc., West Orange, NJ) was given in a dose of 3 to 5 mg i.v. to the fetus to prevent sudden movements. Catheters were inserted into the main pulmonary trunk, right pulmonary artery, and left atrium as previously described (5, 14). Constriction of the ductus arteriosus by pharmacologic interventions during the study was prevented by careful subadventitial infiltration of the ductus arteriosus with 10% buffered formalin colored with methylene blue according to previously described techniques (15). For continuous measurement of the left pulmonary arterial blood flow, a cuff-type electromagnetic flow transducer (C & C Instruments, Los Angeles, CA) was placed around the left pulmonary artery.
The fetal neck was exposed through the same uterine incision, and catheters were introduced into the superior vena cava and ascending aorta via the jugular vein and carotid artery, respectively. For ventilation of the fetus during the experimental protocol, a 4-to 5-mm tracheostomy tube was inserted via a small incision in the midtrachea and advanced toward the carina, and the proximal trachea was ligated. To assure unobstructed drainage of tracheal fluid into the amniotic cavity, the tracheostomy tube was connected to a catheter in the amniotic cavity.
The fetal skin and uterine incisions were closed after replacing amniotic fluid losses with warm 0.9% normal saline. The abdominal incision of the ewe was closed in layers. Two million IU of penicillin G potassium (E.R. Squibb and Sons, Princeton, NJ) and 100 mg of gentamicin sulfate (Central City Medical, Union City, CA) were administered i.v. to the ewe and into the amniotic cavity during the surgery and daily in the postoperative period. The catheters were sealed with heparinized saline and exteriorized through the abdomen to a protective pouch in the left flank of the ewe. The ewe was thereafter allowed to return to her cage for recovery. All surgical and experimental protocols were approved by the Committee on Animal Research, University of California, San Francisco.
Experimental protocol. We performed experiments 72 h after surgery. To block ventilation-induced prostaglandin production, on the day of the experiment a prostaglandin synthetase inhibitor, meclofenamate sodium monohydrate, was given as a bolus of 10 m a g over 10 min, followed by a continuous infusion of 1.5 mg-kg-'-h-' in the inferior vena cava (5, 14). This was infused for 4 h before commencing the experimental protocol, and the infusion was continued at the same rate during the entire experiment. In the experimental group of animals (n = 8), three conditions were studied in the following sequence: 1 ) baseline, 2) bradykinin antagonist infusion (producing complete blockade of bradykinin receptors as evaluated by injection of exogenous bradykinin), and 3) ventilation with 100% oxygen during bradykinin antagonist infusion. The same protocol was repeated in the control group of animals (n = 5) except that, instead of the bradykinin antagonist, normal saline titrated to the same pH (drug vehicle) was infused at the same rate.
Hemodynamic variables. The catheters were connected to Statham P23 Db transducers (Statham Instruments, Oxnard, CA), and pulmonary arterial, descending aortic, left atrial, amniotic, and tracheal pressures were recorded continuously throughout the experimental period on a direct-writing polygraph (Beckman Instruments, Schiller Park, IL). All pressures were corrected using amniotic pressure as the zero reference. For technical reasons, left atrial pressures could not be measured in two fetal lambs in the experimental group, and mean values from other fetal lambs were assigned. Fetal blood samples were obtained from the descending aorta for determination of pH, Pco,, and Po, (Coming 158 Blood Gas Analyzer, Coming Medical, Medfield, MA) as well as Hb concentration and oxygen saturation (OSM2 Hemoximeter, Radiometer, Copenhagen, Denmark).
Pulmonary bloodflow. Pulmonary blood flow was measured both intermittently and continuously using two different techniques. It was measured intermittently by the well-established radionuclide-labeled-microsphere technique (16). One batch of radioactive microspheres (15 pm) was chosen at random from 5 7~o , 'lcr, l S 3~d , l14In, 54 Mn, 95pJb, 113 Sn, %r, and "~n (New England Nuclear, Boston, MA) and injected into the superior vena cava. Reference blood samples were withdrawn from the right pulmonary artery at a rate of 3 to 5 mumin beginning immediately before the injection of microspheres and continuing for at least 40 s after the injection had been completed. Fetal or maternal blood was given to replace the blood lost.
For continuous measurement of left pulmonary arterial blood flow, an electromagnetic flow transducer of appropriate size and precalibrated in vitro using a SP 2202 flowmeter (Statham Instruments) was placed around the left pulmonary artery of all fetal lambs. Such continuous measurement of the pulmonary blood flow allowed us immediately to identify the pulmonary vasodilator responses to bradykinin, acetylcholine, and ventilation with 100% oxygen.
Puiinovuseular reshnce. This was calculated from the difference between mean pulmonary arterial pressure and mean left atrial pressure divided by the pulmonary blood flow calculated by the radioactive microsphere technique.
Buseline. Baseline measurements of arterial blood gases, all hemodynamic variables, and pulmonary blood flow were obtained as the ewe stood quietly in the study cage with free access to food and water. During this baseline condition, small boluses of bradykinin (1 pg/kg) and acetylcholine (0.5 pglkg) were given to assure an intact endothelium-dependent vasodilatory response to these agents and in the case of bradykinin also to establish, before producing bradykinin receptor blockade, the baseline pattern and degree of response to a given dose of bradykinin.
Bradykinin antagonist infusion. In eight animals, infusion of the potent B,-kinin receptor antagonist, [N-ada-
mantaneacetyl-~-~rg~,~yp~,~hi~~,~-~he~]-bradykinin
(Bachem California, Torrance, CA), was started at a rate of 15 to 20 pg.kg-l-min-l. The bradykinin antagonist was dissolved in distilled water and a small volume of normal saline, so that the volume of the vehicle infused would not affect pulmonary blood flow in any manner, and was infused into the main pulmonary artery. Ten min later, bradykinin boluses were given in gradually increasing doses of 1 to 3 pgkg; failure of the left pulmonary arterial blood flow (measured by the electromagnetic flow transducer) to increase with these boluses assured us of complete blockade of the bradykinin receptors. These boluses were separated by 10-min intervals to avoid tachyphylaxis to bradykinin. An acetylcholine bolus (0.5 pgkg) was given during the bradykinin antagonism to assure intact endothelium-dependent vasodilation. Once we were confident of complete blockade of bradykinin receptors, we measured arterial blood gases, hemodynamic variables, and pulmonary blood flow again.
Ventiilotin with 1 W o oxygen during bradykinin antagonist infusion. In all animals, in utero ventilation with 100% oxygen was then started during vehicle infusion (control group) or during infusion of the bradykinin antagonist (experimental group) as a continuation of the previous condition. To achieve uniform distention of the fetal lungs, Exosurf (Burroughs-Wellcome, Research Triangle Park, NC) was instilled into the lungs 1 h before in utero ventilation was started. To ventilate the fetus, the tubes connected to the tracheal tube were opened and tracheal fluid was allowed to drain by gravity. These tubes were then connected to a model 665 animal respirator (Harvard Apparatus, Millis, MA), and the fetus was ventilated with 100% oxygen at a ventilatory rate of 40 to 50 breathslmin, with an inspiratory:expiratory ratio of 0.45 and a tidal volume of 25 to 35 mL. Carbon dioxide was not added to the oxygen because earlier studies had shown that this causes an increase in Pco,, probably due to a decrease in placental blood flow during oxygenation resulting in inadequate removal of carbon dioxide (17).
After 30 min of ventilation, and once hemodynamic stability was achieved, the blood gases, hemodynamic variables, and pulmonary blood flow were measured again. During ventilation, large boluses of bradykinin (3 pg/kg) were given intermittently to ensure continued blockade of bradykinin receptors.
Upon completion of the experiment, the ewe was killed by injection of a large dose of sodium pentobarbital, and the fetus was removed from the uterus and weighed. Catheter positions and the condition of the lungs were evaluated during autopsy of the fetus. The lungs were then removed, weighed, fixed in formalin, cut into small pieces, and placed in plastic vials to a uniform height of 3 cm. Radioactivity of fetal lungs and of reference blood samples was counted in a 1000-channel pulse-height analyzer (Norland, Fort Atkinson, WI). Specific activity of each isotope within a sample was calculated by the leastsquares method (18).
Shtktical anulysis. All data are presented as mean + SD. Blood gases, hemodynamic variables, and pulmonary blood flow measurements were compared between a matched baseline state and during either vehicle (control) or bradykinin antagonist (experimental) infusion by the paired t test with appropriate Bonferroni correction; similarly, measurements during either vehicle or bradykinin antagonist infusion and the subsequent ventilation period for each and also between the matched baseline state and subsequent ventilation were compared within each group (control or experimental) by the paired t test with appropriate Bonferroni correction. The differences between baseline and ventilation between the control and experimental groups were compared by nonpaired t test. A p value of less than 0.05 indicated statistical significance.
RESULTS
The infusion of the bradykinin antagonist failed to prevent or attenuate the oxygen-mediated pulmonary va-sodilation, despite complete blockade of the pulmonary vasodilator effect of exogenous bradykinin (Fig. 1) . The blockade of the action of bradykinin was achieved by the bradykinin antagonist after the latter had been infused for 10 min. We found that, although the bradykinin antagonist had completely neutralized the effect of bradykinin, the pulmonary vasodilatory response to acetylcholine remained unaffected during bradykinin blockade (Fig. 1) . The infusion of the bradykinin antagonist itself did not affect the blood gases (Table I) , pulmonary blood flow, or any other hemodynamic variables (Table 2 ).
In the experimental group receiving the bradykinin receptor antagonist, after 30 min of ventilation with 100% oxygen, the pulmonary blood flow calculated by the radioactive microsphere technique increased by 676% over the baseline state (from 157.8 -c 66 to 1224 2 265 rn~smin-'-100 g-'; p < 0.01) ( Table 2 , Fig. 2 ). This occurred even though the pulmonary vasodilatory effect of bradykinin was completely inhibited. The corresponding pulmonary vascular resistance decreased by 89% compared with the baseline state (from 0.44 + 0.16 to 0.048 2 0.01 torr-m~-'.min-100 g; p < 0.01) (Fig. 2) . During ventilation with 100% oxygen there was no significant decrease in mean pulmonary arterial pressure, but there was a more than 2-fold increase in left atrial pressure (2.7 2 0.8 to 6.8 2 1.9 torr; p < 0.01). Neither the bradykinin antagonist infusion alone nor ventilation with 100% oxygen during the bradykinin antagonist infusion caused any significant change in descending aortic pressure (Table 2 ).
In the control group, the effects of ventilation with 100% oxygen on pulmonary blood flow, pulmonary vascular resistance, and the other hemodynamic variables were not significantly different from those in the experimental group of fetal lambs receiving the bradykinin antagonist ( Table 2, Fig. 2 ). The relative increase in pulmonary blood flow over the baseline state produced by oxygen ventilation was similar in both the control and experimental groups (696% increase in the control group versus 676% increase in the experimental group; p > 0.05). This suggested that bradykinin receptor blockade failed not only to inhibit but also to attenuate the pulmonary vasodilator response to oxygen in fetal lambs.
Whereas the radioactive microsphere technique provided intermittent information about the pulmonary blood flow, more continuous information about the pulmonary blood flow pattern was provided by the electromagnetic flow transducer. This confirmed that, during the infusion of the bradykinin antagonist, flow in the left pulmonary artery remained unchanged. However, when ventilation with 100% oxygen was started, the pulmonary blood flow increased gradually over a period of 10 to 15 min and finally achieved a peak value, usually by 20 min (Fig. 1) . Left pulmonary arterial blood flow, measured by the flow transducer, increased during in utero ventilation with 100% oxygen in both the experimental group (42 ? 24 to 344 ? 86 mWmin; p < 0.01) and the control group (37 + 19 to 318 2 39 mWmin; p < 0.01). There was no significant difference in the relative increase in left pulmonary arterial blood flow produced by ventilation with 100% oxygen between the control and experimental groups (719% increase in the control group versus 759% increase in the experimental group; p > 0.05). This, similar to the radioactive microsphere technique, suggested that bradykinin receptor blockade failed to inhibit or even attenuate oxygen-induced pulmonary vasodilation in fetal lambs.
This state of increased pulmonary blood flow was maintained as long as the fetus was ventilated with 100% oxygen. Once ventilation with 100% oxygen was discontinued, the pulmonary blood flow started to decrease, gradually decreased to a plateau, and finally reached the preventilation baseline state approximately 1.0 to 1.5 h after ventilation was discontinued. 
DISCUSSION
B, receptor antagonists, were able to inhibit this producThe aim of our study was to investigate the role of tion of cyclic GMP in bradykinin-stimulated endothelial bradykinin as one possible intermediary vasoactive sub-cells (25). stance in oxygen-mediated pulmonary vasodilation. We
For these reasons we decided to use a potent B2 reshowed that in fetal lambs complete blockade of brady-ceptor antagonist, [ N -~~~~~~~~~ kinin receptors does not inhibit or attenuate the pulmo-~hi~",~-~he']-bradykinin, to evaluate the role of bradynary vasodilatory response to ventilation with oxygen. kinin in oxygen-induced pulmonary vasodilation in fetal Concentrations of free bradvkinin are higher in umbil-lambs. This bradykinin antagonist is, in fact, an analog -ical venous and arterial cord blood than in maternal venous blood (19) . Also, exogenous bradykinin is a potent pulmonary vasodilator (&lo), and bradykinin is released from fetal lungs with ventilation or during hyperbaric oxygenation (11, 20) . Thus, we considered that bradykinin might be one intermediary substance involved in oxygen-induced pulmonary vasodilation. Recently, the development of specific bradykinin receptor antagonists (21, 22) has allowed further examination of this hypothesis. Bradykinin and related kinins act via two receptors designated as B, and B2 receptors (23) . Bradykinin has a high affinity for binding to the B2 receptors and a low affinity for binding to B, receptors (24) . Both in bovine pulmonary artery endothelial cells and in porcine vascular endothelial cells (24, 25) , stimulation of bradykinin receptors by bradykinin causes the production or release of EDNO. The EDNO enhances the production of cyclic GMP (13, 26), which in turn mediates vascular smooth muscle relaxation. Only B, receptor antagonists, and not bradykinin with amino acid substitutions at positions 3 (proline), 5 (phenylalanine), 7 (proline), and 8 (phenylalanine) with L-Chydroxyproline (Hyp), p-2-thienyl-Lalanine (Thi), ~-phenylalanine (D-Phi), and p-2-thienyl-Lalanine (Thi), respectively. In addition to these substitutions, adamantaneacetyl-D-arginine is added to the N-terminal residue (21, 22). This bradykinin analog is a competitive antagonist of bradykinin and is more potent than some of the B2 receptor antagonists synthesized earlier (22, 24). The B2 receptor blockade is dose dependent (24) and, in our studies at a continuous infusion rate of 60 &min (15-20 pg.kg-l-min-l), it completely blocked the pulmonary vasodilator action of bradykinin. Repeated boluses of gradually increasing doses of bradykinin failed to elicit a pulmonary vasodilator response during infusion of this bradykinin antagonist.
The continuous infusion of a bradykinin antagonist failed to prevent or attenuate the significant pulmonary vasodilation caused by oxygen in fetal lambs. This indi- --In summary, this study in fetal lambs shows that bradykinin receptor blockade does not inhibit or attenuate the well-known pulmonary vasodilatory response caused by oxygen, thereby suggesting that bradykinin release is not essential for oxygen-induced pulmonary vasodilation. It H is possible that oxygen acts mainly by the release of EDNO in the endothelium or by a direct effect on the vascular smooth muscle.
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